Table 3.
Failure patterns during treatment courses.
| mFOLFIRINOX | GOFL | |||||||
|---|---|---|---|---|---|---|---|---|
| Induction CT (N = 27) | Peri-5-FU CCRTa (N = 21) | Maintenance/adjuvant CT (N = 8) | Subtotal | Induction CT (N = 27)b | Peri-Gem-CCRTa (N = 17) | Maintenance/adjuvant CT (N = 9) | Subtotal | |
| Withdrawal/AE | 2 | 2 | 5 | 9 | 1 | 3 (1c) | 4 | 8 |
| Local PD only | 1 | 1 | 1 | 3 | 4 | 1 (1) | 3 | 8 |
| Distant ± local PD | 3 | 10 (3d) | 2 | 15 | 5 | 4 (2e) | 1 | 10 |
| Progression-free | – | – | – | – | – | – | 1 | 1 |
| Subtotal | 6 | 13 | 8 | 27 | 10 | 8 | 9 | 27 |
AE adverse events, CT chemotherapy, CCRT concurrent chemoradiotherapy, PD disease progression.
aPeri-CCRT including those detected during laparotomy, total case (detected during laparotomy).
bExclude one ineligible patient who had metastatic disease upon diagnosis.
cWithdrawal due to unresectable disease with arterial encasement for subsequent therapy.
dPeritoneal seeding was noted during laparotomy in all three patients.
ePeritoneal seeding was noted during laparotomy in one and liver metastases within 4 weeks after R1 resection in one.